Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
21.16
+0.36 (+1.73%)
Streaming Delayed Price
Updated: 11:16 AM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Veracyte to Participate in Upcoming Investor Conferences
May 23, 2023
From
Veracyte, Inc.
Via
Business Wire
Here's Why This Little-Known Growth Stock Is a Buy
May 22, 2023
Analysts think this genomic test maker could have major upside in the next year.
Via
The Motley Fool
Looking Into Veracyte's Return On Capital Employed
May 17, 2023
Via
Benzinga
Time To Play Small Cap Life Science Stocks
May 15, 2023
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.
Via
Talk Markets
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Recap: Veracyte Q1 Earnings
May 04, 2023
Via
Benzinga
A Preview Of Veracyte's Earnings
February 21, 2023
Via
Benzinga
A New Groundbreaking Tool to Detect Colon Cancer Earlier
May 10, 2023
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This...
Via
PressReach
Exposures
Product Safety
Something Happened In Biotech Last Week
May 08, 2023
Biotech stocks were more constructive last week with some sharp moves up.
Via
Talk Markets
Veracyte Announces First Quarter 2023 Financial Results
May 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
May 04, 2023
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For May 4, 2023
May 04, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Via
Benzinga
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
May 03, 2023
From
Veracyte, Inc.
Via
Business Wire
New Artificial Intelligence Tool Can Diagnose Colon Cancer
May 03, 2023
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and...
Via
PressReach
Topics
Artificial Intelligence
Death
Exposures
Artificial Intelligence
Death
Product Safety
Veracyte Announces Release of Inaugural ESG Report
May 03, 2023
From
Veracyte, Inc.
Via
Business Wire
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
May 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
May 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
April 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
April 27, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
April 17, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
April 13, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
April 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
April 01, 2023
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...
Via
Talk Markets
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
March 15, 2023
From
Veracyte, Inc.
Via
Business Wire
7 Biotech Stocks That Could Be the Next Big Thing
March 15, 2023
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Via
InvestorPlace
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
March 11, 2023
From
Veracyte, Inc.
Via
Business Wire
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?
March 10, 2023
This diagnostics test maker has held up well over the last year.
Via
The Motley Fool
Veracyte to Participate in Upcoming Investor Conferences
February 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
February 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For February 22, 2023
February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.